Peer Review History

Original SubmissionAugust 18, 2021
Decision Letter - Giordano Madeddu, Editor

PONE-D-21-26734Latent syphilis in HIV treatment-experienced Ethiopians: Investigating risk factors, neurosyphilis, and response to therapy.PLOS ONE

Dear Dr. Amogne,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jan 08 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Giordano Madeddu

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf.

2. Thank you for stating the following in the Financial Section of your manuscript:

“The research was supported by a Medical Education Partnership Initiative (MEPI) grant for junior faculty members (D43TW010143) obtained from the US National Institutes of Health, Fogarty International Center. The funder had no role in the study design, conduct, data collection, analysis, publication decision, or manuscript preparation. The grant received was to conduct the study and does not cover expenses related to the manuscript preparation and publication. “

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

“The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

3. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The study presents results of original study. The study objectives were clearly set out. Methodology, statistics were performed with high technical standards and adequately described. The conclusions are appropriately supported with data. The paper is well written in standard English.

In the background, addition of syphilis prevalence in the area of study or Ethiopian general population or pregnant women would give context to the reader.

Reviewer #2: Full title: Latent syphilis in HIV treatment-experienced Ethiopians: investigating risk factors, neurosyphilis, and response to therapy. 4 Short title: Latent syphilis in HIV coinfected Ethiopians

Many typos are present in the text, such as capital letters (e.g., line 61 “Syphilis”, and grammar mistakes. Please re-read the manuscript carefully and fix them.

Abbreviations should be written entirely in the first appearance in the text (e.g., SD)

Title

I suggest removing “neurosyphilis” from the title.

I suggest modifying the short title in Latent syphilis in Ethiopians living with HIV

Introduction

I suggest deleting “Syphilis is a major global health problem.” and starting with “The World Health […].

Many sentences seem to be disconnected from the rest of the text (e.g. lines 44 “Neurosyphilis risk increases with HIV coinfection”). I suggest you read the manuscript carefully and try to create a more flowing text.

Furthermore, I suggest you add that people with HIV that have a viral load <200copies/mL and a STD still does not transmit HIV, adding these two references https://doi.org/10.1097/QAD.0000000000002825 and https://doi.org/10.1016/S0140-6736(19)30418-0.

The authors wrote, “Frequently PWH are diagnosed with latent syphilis without being aware of prior symptomatic disease” I suggest not using “frequently,” but write the percentage if you have one.

Methods

The authors wrote, “The indications were RPR titer > 1:32, peripheral blood CD4 count < 350 cells/mm3 if the HIV RNA level is above 200 copies/mL” and “We included the HIV RNA level criterion to exclude immunological nonresponders (a category of HIV-infected patients on cART who have suppressed HIV viremia but a suboptimal increase in their CD4 cell count)”.

This part is unclear. Neurosyphilis could also be present in people with more than 350 CD4/mm3. Please comment.

The definition of neurosyphilis, in my opinion, is not correct. The authors wrote “. Neurosyphilis was diagnosed with a reactive cerebrospinal fluid (CSF) venereal disease research laboratory (VDRL) test result or the presence of CSF pleocytosis (WBC > 10 cells/mm3)”. Therefore, I suppose that a patient with negative CSF VDRL but 11 WBC in the CFS was considered positive to neurosyphilis, and it could represent an important bias that could cause an overrate of neurosyphilis. Please comment.

Have patients with a diagnosis of latent syphilis performed an ophthalmic evaluation? Please comment

The authors wrote “The latent syphilis cases were assigned to receive treatment with three weekly intramuscular injections of BPG 2.4 million units”. I think that they mean one intramuscular injection for three weeks. Please comment.

Tables. Please add a caption in each table explaining the abbreviations’ meaning.

Table 1. Please write the number of people included in the study in the title. Instead of using the ratio of male/female, write the percentage of them. Please modify “History of STI, self (n,%)” with “previous STI diagnosis (n,%).

It is not clear what “Practice condom use, any (n,%)” means. Please comment

The author wrote “Baseline CD4 count (median, IQR)”. However, it is not clear what baseline means.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

It's attached in a letter as response to reviewers.

Decision Letter - Giordano Madeddu, Editor

PONE-D-21-26734R1Latent syphilis in HIV treatment-experienced Ethiopians and response to therapy.PLOS ONE

Dear Dr. Amogne,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by May 08 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Giordano Madeddu

Academic Editor

PLOS ONE

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Partly

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: N/A

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: No

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: No

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: The authors have not uploaded the answers' to my previous revision. For this reason, I am not able to perform this review.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 2

Greetings,

We want to thank you for the valuable comments the reviewers gave us to improve the quality of our manuscript. As a result, we did several editorial works to ensure the clarity and continuity of our work. The revised manuscript is attached for your comments. We have also made the raw data available. Below you will find our response to the questions raised by the second reviewer.

Response to the questions raised by reviewer 2:

Question #1: The authors wrote, "The indications were RPR titer > 1:32, peripheral blood CD4 count < 350 cells/mm3 if the HIV RNA level is above 200 copies/mL," and "We included the HIV RNA level criterion to exclude immunological nonresponders (a category of HIV-infected patients on cART who have suppressed HIV viremia but a suboptimal increase in their CD4 cell count)". This part is unclear. Neurosyphilis could also be present in people with more than 350 CD4+ cells/mm3. Please comment.

Authors' response: We accept the section on "diagnosis of neurosyphilis" was not explicit. Therefore, it is written again (refer to page 7). The indications for CSF analysis in our study were a/ serum RPR titer > 1:32 b/peripheral blood CD4 count < 350 cells/mm3, and HIV RNA level above 2.3 log/mL (or 200 copies/mL) c/serological nonresponse or treatment failure after latent syphilis therapy and d/unexplained persistent neurologic, ocular or otic symptoms or signs. CNS invasion with Treponema pallidum in PWH can occur at any stage of syphilis, CD4 count, and RPR titration. It may be asymptomatic or manifests with central nervous system affection symptoms. Asymptomatic neurosyphilis, however, rarely occurs in antiretroviral naïve PWH and syphilis confection with RPR titer values below 1:16 and > 350 peripheral CD4+ cells/mm3. Therefore, it is controversial that this group should require routine CSF evaluation. Several studies have suggested that serum RPR titers > 1:32 or CD4 counts < 350 in treatment naïve HIV-syphilis coinfected patients indicate a higher risk of asymptomatic infection. Thus, the current guidelines recommend evaluating the CSF for neurosyphilis based on these suggestions. The guidelines fail to address the risk of asymptomatic neurosyphilis in PWH with suppressed HIV RNA levels due to combination antiretroviral therapy (cART). In patients with CD4 counts > 350 and RPR titer > 1:32, CSF evaluation is highly recommended regardless of symptoms. There is a potential to miss asymptomatic cases presenting without symptoms and an RPR titer < 1:32 unless CSF analysis is done routinely. Since we didn't perform CSF analysis in all our latent syphilis cases, there is a potential missing, even though it is rare. It is one of our study limitations (page 13, lines 270-71). We didn't expect the RPR titer to show a favorable response with either BPG or DOXY therapy when there is neurosyphilis. It was the reason for including serological nonresponders and treatment failure cases for CSF analysis to rule out neurosyphilis. We conclude that it is quite rare for neurosyphilis to occur without symptoms in PWH on suppressive cART, CD4 above 350, and latent syphilis coinfection, provided the RPR titer value is below 1:32.

Question #2: The authors wrote, "Neurosyphilis was diagnosed with a reactive CSF VDRL test or the presence of pleocytosis (WBC > 10 cells/mm3)". Therefore, I suppose that a patient with negative CSF VDRL but 11 WBC in the CSF was considered positive for neurosyphilis. It could represent an important bias that could cause an overrate of neurosyphilis. Please comment.

Have patients with a diagnosis of latent syphilis performed an ophthalmic evaluation? Please comment.

Authors' response. The diagnosis of neurosyphilis is a complex process. CSF WBC count > 10 cells/mm3 is often used as a diagnostic criterion for neurosyphilis in PWH. However, the specificity is lower in PWH, for there are other pleocytosis causes outside of neurosyphilis. If this criterion alone is used, it will certainly lead to an overdiagnosis of neurosyphilis, particularly in PWH without symptoms. The level of uncertainty would decrease if both criteria are used together (CSF VDRL and WBC > 10 cells/mm3); however, the problem is the CSF VDRL lacks sensitivity. Even if using this criterion, none of the seven CSF we analyzed supported the diagnosis of neurosyphilis, implying syphilis disease activity is reduced in the latent stage. We conclude that neurosyphilis from latent syphilis infection is rare in PWH receiving virus suppressive cART and RPR titers below 1:32.

We did ophthalmic examination in cases diagnosed with latent syphilis ( page 6, lines 121-122).

Attachments
Attachment
Submitted filename: Response to the reviewers 5-15-2022.docx
Decision Letter - Giordano Madeddu, Editor

Latent syphilis in HIV treatment-experienced Ethiopians and response to therapy.

PONE-D-21-26734R2

Dear Dr. Amogne,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Giordano Madeddu

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: the authors have adequately addressed my comments, and in my opinion the manuscript is now suitable to be publish

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

**********

Formally Accepted
Acceptance Letter - Giordano Madeddu, Editor

PONE-D-21-26734R2

Latent syphilis in HIV treatment-experienced Ethiopians and response to therapy.

Dear Dr. Degu:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Giordano Madeddu

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .